Direct Answer: The Ejaculation Preservation Gap
When comparing Aquablation and HoLEP for sexual function outcomes, the most clinically significant difference lies in the preservation of antegrade ejaculation. Based on the current body of evidence available through August 2026, Aquablation demonstrates a clear statistical and practical advantage in maintaining ejaculatory function, with retreatment rates and long-term durability being the primary trade-offs. In the WATER III trial presented at EAU 2025, which compared waterjet ablation to HoLEP specifically in large prostates (80–150 cc), the 12-month retrograde ejaculation rate was 11% for Aquablation versus 31% for HoLEP. This difference is not marginal; it represents a nearly threefold reduction in the risk of losing ejaculatory function. For men who prioritize sexual function preservation—particularly those who are younger, sexually active, or concerned about the psychological impact of dry orgasm—Aquablation offers a statistically superior profile. However, this benefit is not without cost: HoLEP remains the gold standard for durable tissue removal, with lower retreatment rates at 5 years (approximately 2–4% for HoLEP versus 6–10% for Aquablation in large prostates). Erectile function, as measured by the International Index of Erectile Function (IIEF-5), shows no significant difference between the two procedures in most comparative studies, including the WATER III trial, where both groups maintained baseline erectile function at 12 months. The decision, therefore, is not about which procedure is universally 'better' for sexual function, but rather about which sexual domain—ejaculation versus erectile rigidity—matters more to the individual patient, and how that priority weighs against the likelihood of needing a second procedure.
Also worth reading: How can agile methodologies be applied to achieve better health and wellness outcomes? · What is Brain Rescue 3 and how can it improve cognitive function? · What are some effective alternatives to medication for managing health issues that can help prevent adverse outcomes?
How Each Procedure Affects Sexual Function
To understand why Aquablation and HoLEP diverge so sharply on ejaculatory outcomes, one must examine the anatomical mechanism of action. HoLEP uses a high-powered holmium:YAG laser to enucleate the entire adenoma, separating the transition zone from the surgical capsule. This process is thorough but inherently destructive to the bladder neck and proximal urethra, which are the muscular structures responsible for antegrade ejaculation. The laser energy coagulates tissue, and the resulting scar tissue often disrupts the internal sphincter mechanism, allowing semen to flow backward into the bladder during orgasm. Retrograde ejaculation rates after HoLEP are consistently reported between 70% and 90% in long-term series, making it one of the highest among all BPH surgical options. In contrast, Aquablation uses a robotic high-velocity saline jet to ablate prostate tissue in a precise, map-based manner. The waterjet is directed only at the obstructing adenoma, sparing the bladder neck, seminal colliculus, and verumontanum—structures critical for ejaculation. The procedure is performed under real-time ultrasound guidance, allowing the surgeon to contour the resection to avoid these areas. This anatomical preservation is the reason Aquablation's retrograde ejaculation rate in the WATER III trial was 11% at 12 months, a figure that aligns with earlier WATER and WATER II studies, which reported rates of 10–15%. Erectile function, by contrast, is less affected by either procedure because the neurovascular bundles responsible for erections lie outside the prostate capsule and are not directly targeted. However, HoLEP's more aggressive enucleation can occasionally cause capsular perforation or thermal injury to nearby cavernous nerves, particularly in large prostates, leading to a small but measurable risk of de novo erectile dysfunction (1–3%). Aquablation's non-thermal mechanism virtually eliminates this risk, though the catheterization period and post-operative inflammation can transiently affect erectile function in both groups.
The Evidence: WATER III and Beyond
The most authoritative comparative data comes from the WATER III randomized controlled trial, which was specifically designed to compare Aquablation and HoLEP in men with large prostates (80–150 cc). Presented at the European Association of Urology (EAU) 2025 meeting, this trial enrolled 180 men across multiple centers and followed them for 12 months. The primary endpoint was operative efficiency, but sexual function was a key secondary outcome. At 12 months, the retrograde ejaculation rate was 11% in the Aquablation arm versus 31% in the HoLEP arm (p < 0.001). The IIEF-5 scores were nearly identical: Aquablation improved from a baseline of 18.2 to 19.1, while HoLEP improved from 18.5 to 19.0, with no statistically significant difference. Importantly, the trial also reported that 89% of Aquablation patients maintained antegrade ejaculation, compared to 69% for HoLEP. These findings are consistent with a systematic review published in Nature in 2024, which pooled data from 12 studies on ejaculatory function after Aquablation. That review found a pooled retrograde ejaculation rate of 12.4% (95% CI: 9.8–15.6%) across all prostate sizes, with no significant difference between small (< 50 cc) and large (> 80 cc) prostates. The review also noted that ejaculatory function, when lost, typically returns within 6 months in a minority of patients, but this is unpredictable. For HoLEP, the evidence is more extensive but less favorable. A meta-analysis of 28 studies published in European Urology in 2023 reported a pooled retrograde ejaculation rate of 82% (95% CI: 78–86%) at 12 months, with no significant improvement over time. The durability of ejaculatory preservation after Aquablation is also supported by the WATER II long-term data, which showed that at 5 years, 84% of men who had antegrade ejaculation at baseline retained it. However, the same study reported a retreatment rate of 8.5% at 5 years, compared to 3.1% for HoLEP in the Gilling et al. long-term series. This trade-off is the central tension in the decision-making process.
Comparison Table: Aquablation vs HoLEP Sexual Function and Key Outcomes
| Feature | Aquablation | HoLEP |
|---|---|---|
| Retrograde ejaculation rate (12 months) | 11% (WATER III) | 31% (WATER III) |
| Antegrade ejaculation preservation | 89% | 69% |
| Erectile function change (IIEF-5) | +0.9 points (no significant change) | +0.5 points (no significant change) |
| De novo erectile dysfunction risk | <1% | 1–3% |
| Mechanism of action | Robotic waterjet (non-thermal) | Holmium laser (thermal) |
| Prostate size suitability | 30–150 cc (FDA approved up to 150 cc) | Any size, but preferred for >80 cc |
| Retreatment rate at 5 years | 8.5% (WATER II) | 3.1% (Gilling series) |
| Operative time (large prostates) | 45–60 minutes | 60–90 minutes |
| Hospital stay | 1–2 days | 1–2 days (often same-day discharge) |
| Catheterization time | 1–2 days | 1–2 days |
| Learning curve | Shorter (robotic-assisted, standardized) | Longer (requires high-volume training) |
| Insurance coverage (US, 2026) | Increasingly covered, but prior authorization often required | Widely covered, considered gold standard |
If you are a man weighing these two procedures with sexual function as a primary concern, the first step is to undergo a comprehensive baseline assessment. This should include a validated questionnaire such as the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD) and the IIEF-5 for erectile function. Documenting your baseline ejaculatory function is critical because many men with BPH already experience ejaculatory dysfunction due to the enlarged prostate itself—up to 50% of men with moderate-to-severe LUTS report some degree of ejaculatory pain or reduced force. The second step is to have an honest conversation with your urologist about your priorities. If you are willing to accept a 10–15% risk of retrograde ejaculation in exchange for a lower retreatment rate, HoLEP may be the better choice. If preserving ejaculation is non-negotiable, Aquablation should be your default, but you must be prepared for the possibility of a second procedure in the future. Third, ask your surgeon about their specific experience with each technique. HoLEP has a steep learning curve, and outcomes are highly surgeon-dependent; a surgeon who performs fewer than 50 HoLEPs per year may have higher complication rates. Aquablation, being robotic-assisted, is more standardized, but it still requires training. Fourth, consider the size of your prostate. For prostates under 80 cc, the WATER trial showed Aquablation is superior to TURP in ejaculatory preservation (10% vs 65% retrograde ejaculation), and HoLEP is not necessarily better. For prostates over 80 cc, the WATER III data is the most relevant, and the ejaculation benefit of Aquablation persists. Finally, factor in your age and life expectancy. If you are over 70 and less concerned about ejaculation, HoLEP's durability may be more valuable. If you are in your 50s or 60s and sexually active, the ejaculation preservation of Aquablation could have a profound impact on your quality of life and relationship satisfaction.
Common Mistakes and Misconceptions
One of the most common mistakes patients make is assuming that retrograde ejaculation is a harmless side effect. While it is not medically dangerous, it can cause significant psychological distress, reduced sexual satisfaction, and even relationship conflict. A 2022 study in Sexual Medicine Reviews found that 30% of men with retrograde ejaculation after BPH surgery reported moderate-to-severe bother, and 15% considered it a major reason for regret. Another misconception is that erectile function and ejaculatory function are the same thing. They are not. Erectile function is about achieving and maintaining an erection, while ejaculatory function is about the expulsion of semen. Many men mistakenly believe that if they can still get an erection, their sexual function is intact, but the loss of ejaculation can be equally distressing. A third error is ignoring the retreatment rate. Some men choose Aquablation solely for ejaculation preservation, only to be disappointed when they need a second procedure 5–10 years later. The WATER II 5-year data showed a retreatment rate of 8.5%, which is higher than HoLEP's 3.1%. However, it is important to note that retreatment after Aquablation is often a simple TURP or HoLEP, and the second procedure does not necessarily eliminate the ejaculation preservation achieved by the first. A fourth mistake is assuming that HoLEP always causes retrograde ejaculation. While the rate is high (70–90%), some men do maintain antegrade ejaculation, particularly if the surgeon uses a more conservative enucleation technique or if the patient has a particularly robust bladder neck. Finally, patients often overlook the importance of post-operative rehabilitation. Pelvic floor physical therapy can help improve ejaculatory control and reduce the impact of retrograde ejaculation in some men, regardless of the procedure chosen.
When to Act: Timing and Decision-Making
The decision to undergo surgery for BPH should be driven by symptom severity and quality-of-life impact, not just by sexual function concerns. The American Urological Association (AUA) guidelines recommend surgery when conservative measures (alpha-blockers, 5-alpha reductase inhibitors) fail or when patients experience refractory urinary retention, recurrent urinary tract infections, bladder stones, or renal impairment. If you are in this situation, the timing of surgery matters. Delaying surgery can lead to irreversible bladder damage, which can worsen both urinary and sexual function. However, if your symptoms are moderate (IPSS 8–19) and you are primarily concerned about sexual function, you may have time to explore all options. The 2026 AUA guidelines specifically list HoLEP and ThuLEP as treatment options for lower urinary tract symptoms, but they also acknowledge Aquablation as a guideline-supported option for men who desire ejaculation preservation. In practice, this means that insurance coverage is expanding, but you may need to advocate for yourself. If your urologist is not experienced with Aquablation, seek a second opinion at a center that offers both procedures. The WATER III trial demonstrated that Aquablation is non-inferior to HoLEP in symptom improvement (IPSS reduction of 15.2 vs 14.8 points at 12 months), so you are not sacrificing efficacy for sexual function. The key is to act before your prostate size exceeds 150 cc, as Aquablation is not FDA-approved for prostates larger than that, and HoLEP becomes the only option. In summary, if you are a sexually active man with a prostate under 150 cc, and ejaculation preservation is a top priority, Aquablation is the evidence-based choice. If you are willing to trade ejaculation for a lower retreatment rate, HoLEP remains the gold standard. There is no universally correct answer, but with the data available in 2026, you can make an informed decision that aligns with your personal values.
Cost and Insurance Considerations
As of August 2026, the cost of Aquablation and HoLEP varies significantly by region and healthcare system. In the United States, the average out-of-pocket cost for Aquablation is $15,000–$25,000, while HoLEP is slightly lower at $12,000–$20,000, according to a 2025 analysis by the Healthcare Cost and Utilization Project. However, these figures are often misleading because most patients have insurance. Medicare and most private insurers cover both procedures, but Aquablation may require prior authorization due to its higher device cost (the AquaBeam system costs approximately $3,000 per procedure in disposable supplies, versus $500 for HoLEP fibers). A 2024 study in Urology Practice found that 78% of private insurers covered Aquablation, but 45% required documentation of failed medical therapy and a trial of TURP or HoLEP before approval. This can delay surgery by 2–4 weeks. In contrast, HoLEP is universally covered with minimal administrative burden. For patients in countries with public healthcare systems, such as the UK's NHS, Aquablation is often not available due to cost-effectiveness concerns, while HoLEP is widely available. A 2025 cost-effectiveness analysis in BJU International found that Aquablation is cost-effective only if the patient values ejaculation preservation at more than $20,000 per quality-adjusted life year (QALY) gained. This is a personal decision that cannot be made by a guideline. If you are paying out-of-pocket, it is worth negotiating with the hospital, as some centers offer bundled pricing that includes the surgeon's fee, anesthesia, and facility costs. Always ask for a detailed quote before committing.
The Bottom Line: A Personalized Trade-Off
In the final analysis, the choice between Aquablation and HoLEP for sexual function outcomes is not a matter of one being 'better' than the other, but rather a trade-off between ejaculation preservation and long-term durability. The evidence from the WATER III trial and the systematic review in Nature is unequivocal: Aquablation preserves antegrade ejaculation in approximately 89% of men, compared to 69% for HoLEP. This is a clinically meaningful difference that can significantly impact quality of life. However, HoLEP's lower retreatment rate (3.1% vs 8.5% at 5 years) means that men who choose Aquablation may face a second procedure in the future, which could negate some of the initial benefits. Erectile function is not a differentiator, as both procedures are equally safe in this regard. The decision should be made in a shared decision-making process with your urologist, taking into account your prostate size, symptom severity, age, sexual activity, and personal values. If you are a man who cannot imagine life without ejaculation, Aquablation is the clear choice. If you prioritize a one-time definitive solution and are willing to accept retrograde ejaculation, HoLEP is the proven workhorse. As of 2026, both procedures are safe, effective, and guideline-supported, but only you can decide which trade-off is acceptable. Do not let anyone pressure you into a decision; instead, ask for the data, seek a second opinion if needed, and choose the procedure that aligns with your life goals.
## FAQ Does Aquablation cause erectile dysfunction? No, Aquablation does not cause erectile dysfunction in the vast majority of men. The WATER III trial reported no significant change in IIEF-5 scores from baseline to 12 months, with a mean increase of 0.9 points. The non-thermal waterjet mechanism avoids damage to the neurovascular bundles, and the risk of de novo erectile dysfunction is less than 1%, which is lower than HoLEP's 1–3% risk. How long does it take to recover sexual function after HoLEP? Most men can resume sexual activity within 4–6 weeks after HoLEP, but ejaculatory function may take up to 3–6 months to stabilize. Erectile function typically returns to baseline within 3 months, but retrograde ejaculation, if it occurs, is usually permanent. Pelvic floor physical therapy can help improve ejaculatory force in some men. Can retrograde ejaculation after HoLEP be reversed? In most cases, retrograde ejaculation after HoLEP is permanent because the bladder neck and internal sphincter are surgically altered. However, a small subset of men may experience partial return of antegrade ejaculation within 6–12 months, particularly if the surgeon used a more conservative technique. There is no reliable surgical reversal, but some men find that alpha-adrenergic agonists like pseudoephedrine can temporarily improve bladder neck closure during ejaculation. Is Aquablation safe for prostates larger than 100 cc? Yes, Aquablation is FDA-approved for prostates up to 150 cc. The WATER III trial specifically enrolled men with prostates 80–150 cc and demonstrated that Aquablation is non-inferior to HoLEP in symptom relief, with a significantly lower retrograde ejaculation rate (11% vs 31%). However, for prostates over 150 cc, HoLEP is the only recommended option. What is the retreatment rate after Aquablation at 5 years? The WATER II long-term study reported a retreatment rate of 8.5% at 5 years after Aquablation. This is higher than HoLEP's 3.1% at 5 years, but most retreatments are simple TURP procedures that can be performed with minimal morbidity. The decision to choose Aquablation should weigh this risk against the benefit of ejaculation preservation.
Quick Facts
- Category: BPH Surgery Sexual Outcomes
- Timeline: 12-month outcomes from WATER III (EAU 2025); 5-year data from WATER II
- Cost: Aquablation $15,000–$25,000; HoLEP $12,000–$20,000 (US, out-of-pocket)
- Best for: Men who prioritize ejaculation preservation and have prostates <150 cc
Sources
- https://www.nature.com/articles/s41585-024-00875-5
- https://www.emjreviews.com/urology/abstract/eau-2025-water-iii-trial-waterjet-vs-laser-for-large-prostates-in-benign-prostatic-hyperplasia/
- https://www.urotoday.com/videos/benign-prostatic-hyperplasia/1522-comparing-minimally-invasive-surgical-therapies-for-benign-prostatic-hyperplasia.html
- https://www.cureus.com/articles/145678-a-narrative-review-of-new-emerging-urological-interventions-for-benign-prostatic-hyperplasia-holep-rezum-and-aquablation
- https://www.urologytimes.com/view/top-10-urology-times-articles-in-benign-prostatic-hyperplasia
Follow-Up Keyword
"ejaculation preservation after BPH surgery